GENE ONLINE|News &
Adaptimmune Therapeutics Breaks Rough Patch With New Multibillion-Dollar Collaboration
The shares of the UK-based biopharmaceutical Adaptimmune Therapeutics have had a rough year, with its stock down more than 35% between the beginning of January and mid-August of this year. In comparison, the SP500 index was up more than 20% at the same time.
On September 7th, UK-based biopharmaceutical, Adaptimmune's stock jumped almost 29% following the news that it has signed a collaboration deal worth up to $3 billion with Genentech.
As part of the deal, Adaptimmune will receive $150 million in cash upfront, $150 million more over the next five years, and developmental, regulatory, and commercial milestones potentially worth more than $3 billion. In addition, the company will receive royalties from the products they develop.
On September 7th, UK-based biopharmaceutical, Adaptimmune's stock jumped almost 29% following the news that it has signed a collaboration deal worth up to $3 billion with Genentech.
As part of the deal, Adaptimmune will receive $150 million in cash upfront, $150 million more over the next five years, and developmental, regulatory, and commercial milestones potentially worth more than $3 billion. In addition, the company will receive royalties from the products they develop.
GO Prime with only $1.49 now
LATEST
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
